Ekso Bionics(R) to Establish Headquarters in Freiburg, Germany; Strengthens European Expansion Efforts
Donnerstag, 12.11.2015 13:05 von DGAP
DGAP-News: Ekso Bionics
Ekso Bionics(R) to Establish Headquarters in Freiburg, Germany;
Strengthens European Expansion Efforts
12.11.2015 / 13:00
---------------------------------------------------------------------
Freiburg-Based Headquarters to Provide Enhanced Support and Services to
Developing Markets
RICHMOND, Calif., 2015-11-12 13:00 CET (GLOBE NEWSWIRE) --
Ekso Bionics Holdings, Inc. (OTCQB:EKSO), a leading global robotic exoskeleton
company, announced today that it has established a new regional headquarters,
based in Freiburg, Germany, to further strengthen its European presence and
better serve German-speaking markets. The expansion is being led by Ruediger
Hausherr, President, EMEA, Ekso Bionics, and marks an integral step in the
company's development of its Europe, Middle East, and Africa (EMEA) business.
'Establishing this Germany-based subsidiary will allow us to enhance our
customer service with training, education, and field service support by being
in closer proximity to our valued customers,' said Hausherr. 'The Freiburg
headquarters will also position Ekso to build strategic partnerships in the
area.'
This new site further supports Ekso Bionics' European operations by
facilitating regional growth plans, establishing a dedicated sales and customer
service organization to more closely liaise with leading rehabilitation centers
in the region including existing customers such as Swiss Paraplegic Centre
(SPC), Uppsala University Hospital, Sunnaas Hospital, BG Clinics and Schon
Klinik Bad Aibling to name a few.
'We are excited to further expand our European business to meet a rise in
demand for our advanced technology,' said Thomas Looby, President and Chief
Commercial Officer of Ekso Bionics. 'I am pleased to see how Ruediger and the
EMEA team have strengthened our business since he joined us in early October.
Our presence in Western Europe is a strategic part of our market development
and demonstrates our commitment to operational excellence.'
About Ekso Bionics
Since 2005, Ekso Bionics has been pioneering the field of robotic exoskeletons,
or wearable robots, to augment human strength, endurance and mobility. The
company's first commercially available product called Ekso has helped thousands
of people living with paralysis take millions of steps not otherwise possible.
By designing and creating some of the most forward-thinking and innovative
solutions for people looking to augment human capabilities, Ekso Bionics is
helping people rethink current physical limitations and achieve the remarkable.
Ekso Bionics is headquartered in Richmond, CA and is listed on the OTC QB under
the symbol EKSO. www.eksobionics.com
Forward-Looking Statements
Any statements contained in this press release that do not describe historical
facts may constitute forward-looking statements. Forward-looking statements may
include, without limitation, statements regarding (i) the plans and objectives
of management for future operations, including plans or objectives relating to
the design, development and commercialization of human exoskeletons, (ii) a
projection of financial results, financial condition, capital expenditures,
capital structure or other financial items, (iii) the Company's future
financial performance and (iv) the assumptions underlying or relating to any
statement described in points (i), (ii) or (iii) above. Such forward-looking
statements are not meant to predict or guarantee actual results, performance,
events or circumstances and may not be realized because they are based upon the
Company's current projections, plans, objectives, beliefs, expectations,
estimates and assumptions and are subject to a number of risks and
uncertainties and other influences, many of which the Company has no control
over. Actual results and the timing of certain events and circumstances may
differ materially from those described by the forward-looking statements as a
result of these risks and uncertainties. Factors that may influence or
contribute to the inaccuracy of the forward-looking statements or cause actual
results to differ materially from expected or desired results may include,
without limitation, the Company's inability to obtain adequate financing to
fund the Company's operations and necessary to develop or enhance our
technology, the significant length of time and resources associated with the
development of the Company's products, the Company's failure to achieve broad
market acceptance of the Company's products, the failure of our sales and
marketing organization or partners to market our products effectively, adverse
results in future clinical studies of the Company's medical device products,
the failure to obtain or maintain patent protection for the Company's
technology, failure to obtain or maintain regulatory approval to market the
Company's medical devices, lack of product diversification, existing or
increased competition, and the Company's failure to implement the Company's
business plans or strategies. These and other factors are identified and
described in more detail in the Company's filings with the SEC. To learn more
about Ekso Bionics please visit us at www.eksobionics.com. The Company does not
undertake to update these forward-looking statements.
CONTACT: Media Contact:
Heidi Darling, Director of Marketing Communications
Phone: 510-984-1761 x317
E-mail: hdarling@eksobionics.com
Investor Contact:
Chad Rubin, Senior Vice President
Phone: 646-378-2947
E-mail: crubin@troutgroup.com
News Source: NASDAQ OMX
---------------------------------------------------------------------
12.11.2015 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: Ekso Bionics
United States
End of News DGAP News Service
---------------------------------------------------------------------
412397 12.11.2015